BMS 181163
Alternative Names: BMY 30123Latest Information Update: 17 May 1995
At a glance
- Originator Bristol-Myers Squibb
- Class Antiacnes; Antipsoriatics; Retinoids
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acne
Most Recent Events
- 17 May 1995 Discontinued-II for Acne in USA (Unknown route)